An official website of the United States government
Home
Name
Cyramza
Alternate Names
Ramucirumab
Abbreviations
None
Category
Biologic therapy (BRM, immunotherapy)
Subcategory
Antiangiogenesis
Monoclonal antibody
NSC Number
749128
Primary Site
Brain, CNS
Breast
Colorectal
Gastric, GE
Liver
Non-small cell lung cancer (NSCLC)
Ovarian
Prostate
Urinary
Histology
None
Remarks
May 29, 2020: The FDA approved ramucirumab (CYRAMZA) in combination with erlotinib for first-line treatment of metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations.
May 10, 2019: FDA approved ramucirumab (CYRAMZA) as a single agent for hepatocellular carcinoma (HCC) in patients who have an alpha fetoprotein (AFP) of ≥ 400 ng/mL and have been previously treated with sorafenib.
FDA approved ramucirumab for use as a single agent for the treatment of patients with advanced or metastatic gastric or gastroesophageal junction adenocarcinoma with disease progression on or after prior treatment with fluoropyrimidine or platinum containing chemotherapy.
May 10, 2019: FDA approved ramucirumab (CYRAMZA) as a single agent for hepatocellular carcinoma (HCC) in patients who have an alpha fetoprotein (AFP) of ≥ 400 ng/mL and have been previously treated with sorafenib.
FDA approved ramucirumab for use as a single agent for the treatment of patients with advanced or metastatic gastric or gastroesophageal junction adenocarcinoma with disease progression on or after prior treatment with fluoropyrimidine or platinum containing chemotherapy.
Coding
This drug should be coded
